{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:21:31Z","timestamp":1771474891853,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"27-28","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["10037385"],"award-info":[{"award-number":["10037385"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["10041177"],"award-info":[{"award-number":["10041177"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.vaccine.2006.03.023","type":"journal-article","created":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T07:52:14Z","timestamp":1143705134000},"page":"5645-5652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis"],"prefix":"10.1016","volume":"24","author":[{"given":"Manuel","family":"Calvopina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola A.","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge D.","family":"Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Korenaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.03.023_bib1","unstructured":"TDR\/WHO, Scientific Working Group. Report on Leishmaniasis TDR\/SWG\/04. Geneva, Switzerland; 2004. p. 1\u2013137."},{"key":"10.1016\/j.vaccine.2006.03.023_bib2","unstructured":"Croft SL. Drug resistance in leishmaniasis. Scientific Working Group. Report on leishmaniasis TDR\/SWG\/04. Geneva, Switzerland; 2004. p. 108\u201319."},{"key":"10.1016\/j.vaccine.2006.03.023_bib3","series-title":"World class parasites","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4615-0955-4_12","article-title":"Anti-leishmania vaccine","volume":"vol. 4","author":"Campos-Neto","year":"2002"},{"key":"10.1016\/j.vaccine.2006.03.023_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","author":"Handman","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2006.03.023_bib5","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/S0264-410X(00)00109-2","article-title":"Therapy of murine cutaneous leishmaniasis by DNA vaccination","volume":"18","author":"Handman","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.03.023_bib6","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1016\/S0264-410X(03)00527-9","article-title":"Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine","volume":"21","author":"Santos","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.03.023_bib7","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.03.023_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(87)90116-4","article-title":"Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis","author":"Convit","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2006.03.023_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0074-02762004000100010","article-title":"Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus Calmette-Guerin\u2014preliminary report","volume":"99","author":"Convit","year":"2004","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2006.03.023_bib10","first-page":"159","article-title":"Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil","volume":"34","author":"Mayrink","year":"1992","journal-title":"Parassitologia"},{"issue":"2","key":"10.1016\/j.vaccine.2006.03.023_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-4362.2002.01336.x","article-title":"Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial","volume":"41","author":"Machado-Pinto","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.vaccine.2006.03.023_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1590\/S1413-86702001000400008","article-title":"Successful use of a defined antigen\/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report","volume":"5","author":"Badaro","year":"2001","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.03.023_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","article-title":"Second-generation vaccines against leishmaniasis","volume":"21","author":"Coler","year":"2005","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2006.03.023_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1196\/annals.1307.041","article-title":"The immunology of Leishmania infection and the implications for vaccine development","volume":"1026","author":"Vanloubbeeck","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2006.03.023_bib15","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1128\/IAI.73.5.3044-3052.2005","article-title":"Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge","volume":"73","author":"Cluff","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.03.023_bib16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF01525505","article-title":"Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects","volume":"38","author":"Yang","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2006.03.023_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0922-4106(95)90128-0","article-title":"Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo","volume":"291","author":"Hattori","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.vaccine.2006.03.023_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0162-3109(96)00161-0","article-title":"Restoration of immune response in tumor-bearing mice by ONO-4007, an antitumor lipid A derivative","volume":"36","author":"Matsumoto","year":"1997","journal-title":"Immunopharmacology"},{"issue":"2","key":"10.1016\/j.vaccine.2006.03.023_bib19","first-page":"489","article-title":"ONO-4007, a synthetic lipid A analog, induce Th1-type immune response in tumor eradication and restores nitric oxide production by peritoneal macrophages","volume":"23","author":"Matsushita","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1016\/j.vaccine.2006.03.023_bib20","first-page":"1823","article-title":"Profile of cytokines produced in tumor tissue after administration of cyclophosphamide in a combination therapy with tumor necrosis factor","volume":"24","author":"Takiguchi","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.vaccine.2006.03.023_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4889(01)00182-3","article-title":"Toll-like receptors as adjuvant receptors","volume":"1589","author":"Kaisho","year":"2002","journal-title":"Biochem Biophys Acta"},{"key":"10.1016\/j.vaccine.2006.03.023_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.1365-2567.2003.01709.x","article-title":"Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4","volume":"110","author":"Tamai","year":"2003","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2006.03.023_bib23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4269\/ajtmh.2002.67.184","article-title":"Inhibition of intracellular proliferation of Leishmania parasites in vitro and suppression of skin lesion development in BALB\/c mice by a novel lipid A analog (ONO-4007)","volume":"67","author":"Khan","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.03.023_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.0105-2896.2004.00190.x","article-title":"Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniasis or the visceral disease?","volume":"201","author":"McMahon-Pratt","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2006.03.023_bib25","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1128\/IAI.71.8.4278-4288.2003","article-title":"Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis","volume":"71","author":"Ji","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.03.023_bib26","unstructured":"McMahon-Pratt D. Mechanisms of pathogenesis and vaccines. Report of the fourth TDR\/IDRI meeting on second-generation vaccines against leishmaniasis TDR\/PRD\/LEISH\/VAC\/01.1. Yucatan, Mexico; 2001. p. 1\u201313."},{"key":"10.1016\/j.vaccine.2006.03.023_bib27","series-title":"World class parasites","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-4615-0955-4_11","article-title":"The immunology of cutaneous leishmaniasis: experimental infections and human disease","volume":"vol. 4","author":"Farrel","year":"2002"},{"key":"10.1016\/j.vaccine.2006.03.023_bib28","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1126\/science.7403880","article-title":"Human cutaneous Leishmania in a mouse macrophage line: propagation and isolation of intracellular parasites","volume":"209","author":"Chang","year":"1980","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.vaccine.2006.03.023_bib29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2307\/3285671","article-title":"Humoral immune responses among mucosal and cutaneous leishmaniasis patients caused by Leishmania braziliensis","volume":"85","author":"Valli","year":"1999","journal-title":"J Parasitol"},{"key":"10.1016\/j.vaccine.2006.03.023_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.7904381","article-title":"The adjuvant effect of interleukin-12 in a vaccine against Leishmania major","volume":"263","author":"Afonso","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2006.03.023_bib31","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1073\/pnas.96.12.6970","article-title":"Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-\u03b3-dependent mechanisms","volume":"96","author":"Walker","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2006.03.023_bib32","series-title":"Handbook on isolation characterization and cryopreservation of Leishmania","author":"Evans","year":"1989"},{"key":"10.1016\/j.vaccine.2006.03.023_bib33","unstructured":"TDR\/IDRI. Report of the fourth TDR\/IDRI Meeting on second-generation vaccines against Leishmaniasis TDR\/PRD\/LEISH\/VAC\/01.1. Yucatan, Mexico; 2001. p. 1\u201313."},{"key":"10.1016\/j.vaccine.2006.03.023_bib34","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1128\/iai.56.12.3272-3279.1988","article-title":"Membrane glycoprotein M-2 protects against Leishmania amazonensis infection","volume":"56","author":"Champsi","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.03.023_bib35","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1016\/S0264-410X(03)00427-4","article-title":"Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protect BALB\/c and C57BL\/6 mice against cutaneous leishmaniasis","volume":"21","author":"Pinto","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.03.023_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4269\/ajtmh.2004.71.407","article-title":"Protection of C3HEB\/FEJ mice against Leishmania amozonensis challenge after previous Leishmania major infection","volume":"71","author":"Vanloubbeeck","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.03.023_bib37","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.vaccine.2003.06.002","article-title":"Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis","volume":"22","author":"Armijos","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.03.023_bib38","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.trstmh.2005.04.002","article-title":"Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia","volume":"99","author":"Velez","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.03.023_bib39","unstructured":"Aebischer T. Subunit vaccination against cutaneous leishmaniasis: what is to be learned from murine models. Report of the fourth TDR\/IDRI meeting on second-generation vaccines against leishmaniasis TDR\/PRD\/LEISH\/VAC\/01.1. Yucatan, Mexico; 2001. p. 1\u201313."},{"key":"10.1016\/j.vaccine.2006.03.023_bib40","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.4049\/jimmunol.145.12.4306","article-title":"Tumor necrosis factor-alfa synergizes with IFN-gamma in mediating killing of Leishmania major though the induction of nitric oxide","volume":"145","author":"Liew","year":"1990","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2006.03.023_bib41","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/eji.1830181018","article-title":"Interferon-gamma and tumor necrosis factor induce the l-arginine-dependent cytotoxic effector mechanism in murine macrophages","volume":"18","author":"Drapier","year":"1988","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2006.03.023_bib42","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1128\/iai.59.11.3935-3944.1991","article-title":"Role of inorganic nitrogen oxides and tumor necrosis factor alpha in killing Leishmania donovani amastigotes in gamma interferon-lipopolysaccharide-activated macrophages from Lshs and Lshr congenic mouse strains","volume":"59","author":"Roach","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.03.023_bib43","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/IAI.72.2.988-995.2004","article-title":"Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis","volume":"72","author":"Qi","year":"2004","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2006.03.023_bib44","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/nm1210","article-title":"Targeting the innate immune response with improved vaccine adjuvants","volume":"11","author":"Pashine","year":"2005","journal-title":"Nat Med"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2006.03.023_bib45","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0966-842X(02)02426-5","article-title":"Taking toll: lipid A mimetics as adjuvants and immunomodulators","volume":"10","author":"Persing","year":"2002","journal-title":"Trends Microbiol"},{"issue":"5D","key":"10.1016\/j.vaccine.2006.03.023_bib46","first-page":"3957","article-title":"Mechanisms by which chemotherapeutics agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions","volume":"18","author":"Inagawa","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.vaccine.2006.03.023_bib47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1126\/science.1636092","article-title":"Transforming growth factor-b in leishmanial infection: a parasite escape mechanism","volume":"257","author":"Barral-Neto","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2006.03.023_bib48","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.micinf.2005.04.016","article-title":"TGF-B-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens","volume":"7","author":"Olmo","year":"2005","journal-title":"Microb Infect"},{"key":"10.1016\/j.vaccine.2006.03.023_bib49","unstructured":"Barral-Netto M. Differences in IFN-\u03b3 production in vitro predict the pace of in vivo anti-leishmania responses in normal volunteers. Report of the fourth TDR\/IDRI meeting on second-generation vaccines against leishmaniasis TDR\/PRD\/LEISH\/VAC\/01.1. Yucatan, Mexico; 2001. p. 1\u201313."},{"issue":"2","key":"10.1016\/j.vaccine.2006.03.023_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0165-2478(00)00303-5","article-title":"IFN-beta and TGF-beta differentially regulate IL-12 activity in human peripheral blood mononuclear cells","volume":"75","author":"Van Weyenbergh","year":"2001","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2006.03.023_bib51","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1128\/IAI.66.8.3818-3824.1998","article-title":"Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major","volume":"66","author":"Jones","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.03.023_bib52","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.177.6.1797","article-title":"Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response","volume":"177","author":"Sypek","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2006.03.023_bib53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1383-5769(01)00070-8","article-title":"A single intradermal administration of soluble leishmanial antigens and plasmid expressing interleukin-12 protects BALB\/c mice from Leishmania major infection","volume":"50","author":"Yamakami","year":"2001","journal-title":"Parasitol Int"},{"key":"10.1016\/j.vaccine.2006.03.023_bib54","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4049\/jimmunol.165.1.364","article-title":"IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection","volume":"165","author":"Jones","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.03.023_bib55","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.4049\/jimmunol.154.3.1317","article-title":"Endotoxic-mediated dendritic cell release from the intestine: characterization of released dendritic cells and TNF dependence","volume":"154","author":"McPherson","year":"1995","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2006.03.023_bib56","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1128\/IAI.71.6.3337-3342.2003","article-title":"Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial Toll-like receptor activators and skewing of T-cell cytokine profiles","volume":"71","author":"Qi","year":"2003","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2006.03.023_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000053866","article-title":"Lipid A analogue, ONO-4007, inhibit IgE response and antigen-induced eosinophilic recruitment into airways in BALB\/c mice","volume":"127","author":"Iio","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2006.03.023_bib58","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-cell antigens Thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.03.023_bib59","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.20020147","article-title":"Vaccination with heat-killed Leishmania antigen or recombinant leishmanial proteins and CpG oligodeoxinucleotides induce long-term memory CD4+ and Cd8+ T cell responses and protection against Leishmania major infection","volume":"195","author":"Rhee","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2006.03.023_bib60","first-page":"397","article-title":"Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide","volume":"6","author":"de Bono","year":"2000","journal-title":"Clin Cancer Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06002829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06002829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:14:53Z","timestamp":1759400093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06002829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":60,"journal-issue":{"issue":"27-28","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0264410X06002829"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.03.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}